文献速递重症综合管理与镇静镇痛心脑血管急症

高危心脏风险患者术后输血:宽松与限制策略的TOP随机临床试验

Liberal or Restrictive Postoperative Transfusion in Patients at High Cardiac Risk: The TOP Randomized Clinical Trial.
PubMed 文献 · JAMA · 2025-01-01
一句话结论在大血管或普外科术后贫血且心脏事件高危的患者中,宽松输血策略(Hb<10 g/dL触发)相比限制策略(Hb<7 g/dL触发)未降低90天死亡或主要缺血事件。

TOP试验为平行、单盲、随机优效性试验,纳入1428例接受大血管或普外科手术且心脏事件高危的退伍军人,术后Hb<10 g/dL者随机分为宽松策略(Hb<10 g/dL触发输血,714例)或限制策略(Hb<7 g/dL触发,714例)。主要终点为90天内全因死亡、心肌梗死、冠状动脉血运重建、急性肾衰竭或缺血性卒中的复合终点。宽松组主要终点发生率为9.1%(61/670),限制组为10.1%(71/700),相对风险0.90(95%CI 0.65-1.24),未达统计学显著差异。结论认为宽松策略未减少90天死亡或主要缺血结局。

要点

  • 在大血管或普外科术后贫血且心脏事件高危患者中,宽松输血策略(Hb<10 g/dL触发)相比限制策略(Hb<7 g/dL触发)未降低90天主要复合终点(9.1% vs 10.1%,RR 0.90,95%CI 0.65-1.24)。
  • 次要终点中心脏并发症(不含心肌梗死)在宽松组为5.9%(38/647),限制组为9.9%(67/678),相对风险0.59(99%CI 0.36-0.98),为5个次要终点之一。
  • 随机化后第5天,两组平均血红蛋白差异为2.0 g/dL。
  • 研究纳入1428例退伍军人,平均年龄69.9岁(SD 7.9),97.8%为男性,91.1%接受血管外科手术。

适用人群与场景

  • 年龄≥18岁的退伍军人,接受大血管或普外科手术,术后血红蛋白<10 g/dL且心脏事件高危。

诊断标准与关键阈值

  • 术后血红蛋白<10 g/dL为随机化入组阈值。
  • 宽松策略输血触发阈值为血红蛋白<10 g/dL;限制策略输血触发阈值为血红蛋白<7 g/dL。

处置流程与药物剂量

  • 宽松策略:血红蛋白<10 g/dL时输血。
  • 限制策略:血红蛋白<7 g/dL时输血。

研究设计与关键结果

  • 设计:平行、单盲、随机临床优效性试验,纳入1428例退伍军人,来自美国16个退伍军人事务医疗中心, enrollment from February 2018 to March 2023。
  • 干预:714例分配至宽松策略(Hb<10 g/dL触发输血),714例分配至限制策略(Hb<7 g/dL触发输血)。
  • 主要终点:90天内全因死亡、心肌梗死、冠状动脉血运重建、急性肾衰竭或缺血性卒中的复合终点;宽松组9.1%(61/670) vs 限制组10.1%(71/700),相对风险0.90(95%CI 0.65-1.24)。
  • 关键次要终点:心脏并发症(不含心肌梗死,包括心律失常、心力衰竭和非致命性心脏骤停)在宽松组5.9%(38/647) vs 限制组9.9%(67/678),相对风险0.59(99%CI 0.36-0.98)。
  • 随机化后第5天两组平均血红蛋白差异为2.0 g/dL。
  • 纳入分析1424例,平均年龄69.9岁(SD 7.9);1393例男性(97.8%);268例黑人(18.8%);48例西班牙裔(4.1%);1071例白人(75.2%);1297例(91.1%)接受血管外科手术。

证据类型、等级与局限

  • 证据类型:随机对照试验(RCT),优效性设计。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 对于大血管或普外科术后贫血且心脏事件高危的患者,宽松输血策略(Hb<10 g/dL触发)未减少90天死亡或主要缺血事件,与限制策略(Hb<7 g/dL触发)相比主要终点无显著差异。
  • 次要终点中心脏并发症(不含心肌梗死)在宽松组较低(5.9% vs 9.9%,RR 0.59,99%CI 0.36-0.98),但该终点为5个次要终点之一。

指南或共识出处

  • ClinicalTrials.gov Identifier: NCT03229941

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

IMPORTANCE: Postoperative red blood cell transfusion guidelines recommend transfusion for hemoglobin levels less than 7 g/dL. However, the safety of this strategy in patients at high risk of cardiac events undergoing major operations remains unclear.

OBJECTIVE: To evaluate the risk of death or major ischemic events within 90 days after a liberal transfusion strategy compared with a restrictive transfusion strategy in patients at high risk of cardiac events who had undergone major vascular or general surgery operations and developed postoperative anemia.

DESIGN, SETTING, AND PARTICIPANTS: This parallel, single-blind, randomized clinical superiority trial included 1428 veterans (≥18 y) at high cardiac risk undergoing major vascular or general surgery operations. Participants were enrolled from February 2018 to March 2023 across 16 Veterans Affairs Medical Centers in the US.

INTERVENTIONS: Seven hundred fourteen participants with postoperative hemoglobin less than 10 g/dL were randomized to a liberal strategy (transfusion trigger at hemoglobin level <10 g/dL) and 714 to a restrictive strategy (transfusion trigger at hemoglobin <7 g/dL).

MAIN OUTCOMES AND MEASURES: The primary end point was a composite of all-cause death, myocardial infarction, coronary revascularization, acute kidney failure, or ischemic stroke within 90 days after randomization. Secondary end points included a composite of cardiac complications other than myocardial infarction (arrhythmias, heart failure, and nonfatal cardiac arrest).

RESULTS: Of the 1424 analyzed veterans (mean age, 69.9 [SD, 7.9] years; 1393 male [97.8%]; 268 Black [18.8%]; 48 Hispanic [4.1%]; 1071 White [75.2%]), 1297 (91.1%) underwent vascular surgical procedures. The mean hemoglobin difference between transfusion strategies was 2.0 g/dL on day 5 after randomization. The primary outcome rate in the liberal group was 9.1% (61 of 670) compared with 10.1% (71 of 700) in the restrictive group (relative risk, 0.90; 95% CI, 0.65-1.24). The secondary end point of cardiac complications without myocardial infarction, which was 1 of 5 secondary end points, occurred in 5.9% (38 of 647) of patients in the liberal group and 9.9% (67 of 678) of patients in the restrictive group (relative risk, 0.59; 99% CI, 0.36-0.98).

CONCLUSIONS AND RELEVANCE: After major vascular or general surgery operations among patients at high risk of a cardiac event, a liberal transfusion strategy did not reduce 90-day death or major ischemic outcome rates compared with a restrictive strategy.

TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT03229941.

来源:JAMA,查看原文。版权归原作者所有。

参考来源

  1. Kougias P, Sharath SE, Zhan M, et al. Liberal or Restrictive Postoperative Transfusion in Patients at High Cardiac Risk: The TOP Randomized Clinical Trial. JAMA. 2025. PMID: 41205227. doi:10.1001/jama.2025.20841

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。